Drug tendering: drug supply and shortage implications for the uptake of biosimilars

References

• IMS Institute for Healthcare InformaticsGlobal medicines use in 2020: outlook and implications2015 Available from: http://www.imshealth.com/en/thought-leadership/ims-institute/reports/global-medicines-use-in-2020Accessed February 20, 2017
   Google Scholar
• LuYHernandezPAbegundaDEdejerTThe World Medicines Situation 2011: Medicine ExpendituresGenevaWorld Health Organization2011 Available at: http://apps.who.int/medicinedocs/documents/s18767en/s18767en.pdfAccessed February 20, 2017
   Google Scholar
• Deloitte2015 Global health care outlook: common goals, competing priorities2015 Available from: http://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2015-health-care-outlook-global.pdfAccessed February 20, 2017
   Google Scholar
• AdamskiJGodmanBOfierska-SujkowskaGRisk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payersBMC Health Serv Res20101015320529296
   PubMed Web of Science ®Google Scholar
• SchnipperLESmithTJRaghavanDAmerican Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncologyJ Clin Oncol201230141715172422493340
   PubMed Web of Science ®Google Scholar
• VoglerSZimmermannNHablCPiessneggerJBucsicsADiscounts and rebates granted to public payers for medicines in European countriesSouth Med Rev201251384623093898
   PubMedGoogle Scholar
• VoglerSZimmermannNLeopoldCde JoncheereKPharmaceutical policies in European countries in response to the global financial crisisSouth Med Rev201142697923093885
   PubMedGoogle Scholar
• CaroneGSchwierzCXavierACost-containment policies in public pharmaceutical spending in the EU2012 Available from: http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdfAccessed December 20, 2016
   Google Scholar
• IMS Institute for Healthcare InformaticsThe Global Use of Medicines: Outlook Through 2016Parsippany (NJ)IMS Health2012 Available at: www.imshealth.com/files/web/IMSH%20Institute/Reports/The%20Global%20Use%20of%20Medicines%20Outlook%20Through%202016/Medicines_Outlook_Through_2016_Report.pdfAccessed February 20, 2017
   Google Scholar
• BaerWHIIMainiAJacobsIBarriers to the access and use of rituximab in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: a physician surveyPharmaceuticals (Basel)20147553054424810947
   PubMedGoogle Scholar
• LammersPCriscitielloCCuriglianoGJacobsIBarriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging marketsPharmaceuticals (Basel)20147994395325232798
   PubMedGoogle Scholar
• McCamishMWoollettGThe state of the art in the development of biosimilarsClin Pharmacol Ther201291340541722318617
   PubMed Web of Science ®Google Scholar
• FoodUSAdministrationDrugScientific considerations in demonstrating biosimilarity to a reference product: guidance for industry2015 Available from: http://www.fda.gov/downloads/drugs/guidance-complianceregulatoryinformation/guidances/ucm291128.pdfAccessed May 20, 2015
   Google Scholar
• GascónPTeschHVerpoortKClinical experience with Zarzio® in Europe: what have we learned?Support Care Cancer201321102925293223903799
   PubMed Web of Science ®Google Scholar
• Management Sciences for HealthManaging the tender processEmbreyMRyanMMDS-3: Managing Access to Medicines and Health TechnologiesArlington (VA)MSH2012401428
   Google Scholar
• Management Sciences for HealthManaging procurementEmbreyMRyanMMDS-3: Managing Access to Medicines and Health TechnologiesArlington (VA)MSH2012321348
   Google Scholar
• World Health OrganizationOperational principles for good pharmaceutical procurement1999 Available from: http://www.who.int/3by5/en/who-edm-par-99-5.pdfAccessed February 20, 2017
   Google Scholar
• World Health OrganizationWHO Expert Committee on Specifications for Pharmaceutical PreparationsWorld Health Organ Tech Rep Ser20149861387 Available at: http://apps.who.int/medicinedocs/en/d/Js21464en/Accessed November 30, 2016
   Google Scholar
• European ParliamentReport on new developments in public procurement 2009/2175[INI])2010 Available from: http://www.europarl.europa.eu/sides/gETDOC.DO?PUBREF=-//EP//NONSGML+REPORT+A7-2010-0151+0+DOC+PDF+V0//ENAccessed September 8, 2017
   Google Scholar
• World Health OrganizationOperational principles for good pharmaceutical procurement1999 Available from: http://www.who.int/3by5/en/who-edm-par-99-5.pdfAccessed February 20, 2017
   Google Scholar
• GarattiniLVan de VoorenKFreemantleNTendering and value-based pricing: lessons from Italy on human papilloma virus vaccinesJ R Soc Med201410714524399770
   PubMed Web of Science ®Google Scholar
• DylstPVultoASimoensSTendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe?Health Policy2011101214615221511353
   PubMed Web of Science ®Google Scholar
• KanavosPSeeleyLVandorosSTender systems for outpatient pharmaceuticals in the European Union: evidence from the Netherlands, Germany and Belgium2009 Available from: http://ec.europa.eu/DocsRoom/documents/7607/attachments/1/translations/en/renditions/pdfAccessed February 20, 2017
   Google Scholar
• NgorsurachesSChaiyakanKEquitable prices of single-source drugs in ThailandAppl Health Econ Health Policy201513438939725894738
   PubMed Web of Science ®Google Scholar
• DylstPVultoASimoensSSocietal value of generic medicines beyond cost-saving through reduced pricesExpert Rev Pharmacoecon Outcomes Res201515470171125695926
   PubMed Web of Science ®Google Scholar
• Generics and Biosimilars InitiativeGenerics makers to be penalized for huge price hikes2015 Available from: http://www.gabionline.net/Policies-Legislation/Generics-makers-to-be-penalized-for-huge-price-hikesAccessed February 17, 2017
   Google Scholar
• DylstPSimoensSGeneric medicine pricing policies in Europe: current status and impactPharmaceuticals (Basel)20103347148127713264
   PubMedGoogle Scholar
• Generics and Biosimilars InitiativeTendering for medicines in ambulatory care2011 Available from: http://www.gabionline.net/layout/set/print/content/view/full/1446Accessed February 15, 2017
   Google Scholar
• Management Sciences for HealthQuality assurance for pharmaceuticalsEmbreyMRyanMMDS-3: Managing Access to Medicines and Health TechnologiesArlington (VA)MSH2012348371
   Google Scholar
• EU Minister for Public Expenditure and ReformEuropean Union (Award of Public Authority Contracts) regulations 20162016 Available from: http://etenders.gov.ie/Media/Default/SiteContent/Legislation-Guides/european_union_award_of_public_authority_contracts_regulations_082016.pdfAccessed December 20, 2016
   Google Scholar
• EuropaBioWhite paper on public procurement of biological medicines2015 Available from: http://www.europabio.org/sites/default/files/europabio_white_paper_on_public_procurement_of_biological_medicines_final.pdfAccessed December 20, 2016
   Google Scholar
• PauwelsKHuysICasteelsMSimoensSDrug shortages in European countries: a trade-off between market attractiveness and cost containment?BMC Health Serv Res20141443825257912
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationManual of policies and proceduresMAPP 4190.1 Rev. 2: drug shortage management2014 Available from: http://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedi-calproductsandtobacco/cder/manualofpoliciesprocedures/ucm079936.pdfAccessed February 20, 2017
   Google Scholar
• De WeerdtESimoensSCasteelsMHuysIClinical, economic and policy implications of drug shortages in the European UnionAppl Health Econ Health Policy201715444144527480539
   PubMed Web of Science ®Google Scholar
• FoxERSweetBVJensenVDrug shortages: a complex health care crisisMayo Clin Proc201489336137324582195
   PubMed Web of Science ®Google Scholar
• LiESubramanianJAndersonSThomasDMcKinleyJJacobsIADevelopment of biosimilars in an era of oncologic drug shortagesDrug Des Devel Ther2015932473255
   PubMed Web of Science ®Google Scholar
• American Society of Health-System PharmacistsCurrent shortages: drug shortages Available from: http://www.ashp.org/shortagesAccessed December 8, 2016
   Google Scholar
• Mazer-AmirshahiMPourmandASingerSPinesJMvan den AnkerJCritical drug shortages: implications for emergency medicineAcad Emerg Med201421670471125039558
   PubMed Web of Science ®Google Scholar
• VentolaCLThe drug shortage crisis in the United States: causes, impact, and management strategiesP T2011361174075722346307
   PubMedGoogle Scholar
• BeckerDJTalwarSLevyBPImpact of oncology drug shortages on patient therapy: unplanned treatment changesJ Oncol Pract201394e122e12823942928
   PubMedGoogle Scholar
• Association of Community Cancer CentersChemotherapy drug shortages2011 Available from: https://accc-cancer.org/advocacy/pdf/2011-Chemo-Drug-Shortages.pdfAccessed December 8, 2016
   Google Scholar
• Office of Science and Data Policy - U.S. Department of Health and Human ServicesEconomic analysis of the causes of drug shortages2011 Available from: https://aspe.hhs.gov/sites/default/files/pdf/108986/ib.pdfAccessed December 9, 2016
   Google Scholar
• TawdeSAParticulate matter in injectables: main cause for recallsJ Pharmacovigilance2014311000e128
   Google Scholar
• ShabushnigJGParticulate matter and visual inspection: industry trends 20152015 Available from: https://www.pda.org/docs/default-source/website-document-library/chapters/presentations/ireland/particulate-matter-and-visual-inspection---industry-trends-2015.pdf?sfvrsn=4Accessed February 28, 2017
   Google Scholar
• ShabushnigJGParticles in injectable pharmaceuticals: industry trends and regulatory requirements2017 Available from: https://websites.godaddy.com/blob/631aa03c-05c1-4540-a27c-adad80e127a5/downloads/05%20-%20PRPQA%202017%20-%20Shabushnig%201-4-2017.pdf?87be8821Accessed February 28, 2017
   Google Scholar
• US Food and Drug AdministrationFrequently asked questions about drug shortages2016 Available from: https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050796.htm#q3Accessed February 28, 2017
   Google Scholar
• De WeerdtESimoensSHombroeckxLCasteelsMHuysICauses of drug shortages in the legal pharmaceutical frameworkRegul Toxicol Pharmacol201571225125825591547
   PubMed Web of Science ®Google Scholar
• HollisAGrootendorstPTendering generic drugs: what are the risks? Available from: http://canadiangenerics.ca/wp-content/uploads/2016/10/TenderingGenericDrugs-WhatAretheRisks_FINAL.pdfAccessed September 4, 2017
   Google Scholar
• International Pharmaceutical Federation (FIP)Report of the International Summit on Medicines ShortageThe HagueFIP2013 Available at: www.fip.org/files/fip/publications/FIP_Summit_on_Medicines_Shortage.pdfAccessed December 8, 2016
   Google Scholar
• IHS MarkitGerman pharmacists criticise discount contracts amid mounting drug shortages concerns2013 Available from: https://www.ihs.com/country-industry-forecasting.html?ID=1065983862Accessed December 6, 2016
   Google Scholar
• European Federation of Pharmaceutical Industries and AssociationsPolicy proposals to minimise medicine supply shortages in Europe2014 Available from: https://www.efpia.eu/media/15427/policy-proposals-to-minimise-medicine-supply-shortages-in-europe-march-2014.pdfAccessed September 4, 2017
   Google Scholar
• IHS Global InsightsGreek MoH introduces three-supplier model for hospital drugs to avoid shortages20143302017
   Google Scholar
• IHS Global InsightsMajor shortages reported across a wide range of drug groups in Greece20173302017
   Google Scholar
• IHS Global InsightsGreek pharmacies “threatened with closure” over drug shortages20163302017
   Google Scholar
• IHS Global InsightsPharmaceutical industry commits to continued supply of Greek market amid referendum uncertainty20153302017
   Google Scholar
• IHS Global InsightsSituation in Greek hospitals deteriorates, causing shortages of supplies and staff20163302017
   Google Scholar
• BocquetFDegrassat-ThéasAPeignéJPaubelPThe new regulatory tools of the 2016 Health Law to fight drug shortages in FranceHealth Policy2017121547147628366432
   PubMed Web of Science ®Google Scholar
• SchweitzerSOHow the US Food and Drug Administration can solve the prescription drug shortage problemAm J Public Health20131035e10e14
   Web of Science ®Google Scholar
• PostmaDde WolfLMDrug shortages in the Netherlands: monitored by FarmancoEur J Hosp Pharm201320Suppl 1A90
   Google Scholar
• European Medicines AgencyGuideline on similar biological medicinal products2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdfAccessed February 1, 2016
   Google Scholar
• World Health OrganizationGuidelines on evaluation of similar biotherapeutic products (SBPs)2009 Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEU-TICS_FOR_WEB_22APRIL2010.pdfAccessed February 1, 2016
   Google Scholar
• DallerJBiosimilars: a consideration of the regulations in the United States and European UnionRegul Toxicol Pharmacol20167619920826732800
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyEuropean public assessment reports by type (biosimilars)2016 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&keyword=Enter%20keywords&searchType=name&alreadyLoaded=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&jsenabled=false&searchGenericType=biosimilars&orderBy=status&pageNo=1Accessed April 26, 2016
   Google Scholar
• US Food and Drug AdministrationCenter for Drug Evaluation and Research: list of licensed biological products with (1) reference product exclusivity and (2) biosimilarity or interchangeability evaluations to date2016 Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM560162.pdfAccessed September 8, 2017
   Google Scholar
• IMS Institute for Healthcare InformaticsDelivering on the potential of biosimilar medicines: the role of functioning competitive markets2016 Available from: http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Biosimi-lar_Brief_March_2016.pdfAccessed February 20, 2017
   Google Scholar
• BocquetFLoubièreAFusierICordonnierALPaubelPCompetition between biosimilars and patented biologics: learning from European and Japanese experiencePharmacoeconomics201634111173118627412251
   PubMed Web of Science ®Google Scholar
• BocquetFPaubelPA long war begins: biosimilars versus patented biologicsJ Med Econ201518121071107326212478
   PubMed Web of Science ®Google Scholar
• Farfan-PortetMIGerkensSLepage-NefkensIVinckIHulstaertFAre biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?Eur J Health Econ201415322322824271016
   PubMed Web of Science ®Google Scholar
• DylstPVultoASimoensSBarriers to the uptake of biosimilars and possible solutions: a Belgian case studyPharmacoeconomics201432768169124803078
   PubMed Web of Science ®Google Scholar
• BocquetFPaubelPFusierICordonnierALLe PenCSinègreMBiosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysisAppl Health Econ Health Policy201412331532624578185
   PubMedGoogle Scholar
• BocquetFPaubelPFusierICordonnierALSinègreMLe PenCBiosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experienceAppl Health Econ Health Policy2015131475925189295
   PubMed Web of Science ®Google Scholar
• Mestre-FerrandizJTowseABerdudMBiosimilars: how can payers get long-term savings?Pharmacoeconomics201634660961626792791
   PubMed Web of Science ®Google Scholar
• PalmerEDeep discounts allow Remicade biosimilar to grab 50% of Norway’s market2015 Available from: http://www.fiercepharma.com/m-a/deep-discounts-allow-remicade-biosimilar-to-grab-50-of-norway-s-marketAccessed February 20, 2017
   Google Scholar
• WelchARThe Norwegian biosimilar phenomenon: from biosimilar to “biogeneric”2016 Available from: https://www.biosimilardevelopment.com/doc/the-norwegian-biosimilar-phenomenon-from-biosimilar-to-biogeneric-0001Accessed February 17, 2017
   Google Scholar
• DornerTStrandVCornesPThe changing landscape of biosimilars in rheumatologyAnn Rheum Dis201675697498226964144
   PubMed Web of Science ®Google Scholar
• AaproMCornesPAbrahamIComparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropeniaJ Oncol Pharm Pract201218217117921610020
   PubMedGoogle Scholar
• BrodszkyVBajiPBaloghOPentekMBudget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countriesEur J Health Econ201415Suppl 1S65S7124832837
   PubMed Web of Science ®Google Scholar
• FoodUSAdministrationDrugFDA Oncologic Drugs Advisory Committee meeting: Zarxio (filgrastim)2015 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting-Materials/Drugs/OncologicDrugsAdvisoryCommittee/UCM428782.pdfAccessed September 4, 2017
   Google Scholar
• DaneseSBonovasSPeyrin-BirouletLBiosimilars in IBD: from theory to practiceNat Rev Gastroenterol Hepatol2017141223127729659
   PubMed Web of Science ®Google Scholar
• BraunJKudrinASwitching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public healthBiologicals201644425726627117857
   PubMed Web of Science ®Google Scholar
• YooDHProdanovicNJaworskiJEfficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension studyAnn Rheum Dis201776235536327130908
   PubMed Web of Science ®Google Scholar
• GollGLOlsenICJorgensenKKBiosimilar infliximab (CT-13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in NorwayPoster presented at: 2016 ACR/ARHP Annual MeetingNovember 11–16, 2016Washington, DC
   Google Scholar
• CurtoSGhislandiSvan de VoorenKDurantiSGarattiniLRegional tenders on biosimilars in Italy: an empirical analysis of awarded pricesHealth Policy20141162–318218724602376
   PubMed Web of Science ®Google Scholar
• European Biopharmaceutical EnterprisesDirective of the European Parliament and of the Council on Public Procurement COM (2011) 896: EBE position paper on tendering of biosimilars/biologicals2012 Available from: https://qed.eu/old-files-dir/EBEPositionPaper.pdfAccessed June 8, 2016
   Google Scholar
• American Chamber of Commerce to the European UnionImproving access to medicines in the European Union: value, measured outcomes and innovation crucial to fostering sustainable healthcare systems2016 Available from: http://www.amchameu.eu/system/files/position_papers/improving_access_to_medicines_in_the_eu_amcham_eu_health-care_june_2016.pdfAccessed February 17, 2017
   Google Scholar
• European Medicines Agency. Human medicines Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=SubmitAccessed February 20, 2017
   Google Scholar
• Generics and Biosimilars initiativeBiosimilars approved in the US2016 Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-the-USAccessed February 17, 2017
   Google Scholar
• Genetic Engineering & Biotechnology News. Biosimilars: 11 drugs to watch2016 Available from: http://www.genengnews.com/the-lists/biosimilars-11-drugs-to-watch/77900135?page=2Accessed February 17, 2017
   Google Scholar
• Generics and Biosimilars InitiativeBiosimilars of rituximab2015 Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximabAccessed April 19, 2017
   Google Scholar
• Generics and Biosimilars InitiativeBiosimilars of trastuzumab2014 Available from: http://gabionline.net/Biosimilars/General/Biosimilars-of-trastuzumabAccessed April 19, 2017
   Google Scholar
• Generics and Biosimilars InitiativeBiosimilars of bevacizumab2014 Available from: http://gabionline.net/Biosimilars/General/Biosimilars-of-bevacizumabAccessed April 19, 2017
   Google Scholar
• Generics and Biosimilars InitiativeBiosimilars of pegfilgrastim2014 Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-of-pegfilgrastimAccessed April 19, 2017
   Google Scholar
• Generics and Biosimilars InitiativeBiosimilars of epoetin alfa2014 Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-of-epoetin-alfaAccessed April 19, 2017
   Google Scholar
• Generics and Biosimilars InitiativeSubsequent entry biologics approved in Canada2014 Available from: http://www.gabionline.net/Biosimilars/General/Subsequent-entry-biologics-approved-in-CanadaAccessed February 28, 2017
   Google Scholar